The drug will target specific genetic mutations prevalent in certain types of cancers
Cureskin aims to disrupt the large and growing skin and hair care industry in India
Completes acquisition of 75% of share capital from Glenmark Pharmaceuticals
With just few days of treatment, the patient started responding well and finally complete clinical resolution of infection was attained
It is the first autotaxin inhibitor to be investigated in cancer patients
Acquisition broadens oncology pipeline with a portfolio of novel T-cell engagers including HPN328 (MK-6070), an investigational delta-like ligand 3 (DLL3) targeting T-cell engager
India is contributing 13% to the global asthma burden and a disproportionate 43% of the global asthma deaths.
Subscribe To Our Newsletter & Stay Updated